ArticleJournal of biomedical science2026

TRKB-based signature identifies high-risk squamous cell carcinoma cases and TRKB blockade reprograms tumor and stromal cells toward suppressive phenotypes.

Valeria Bartolocci et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.